Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

Merck, Codexis design efficient synthesis of Phase II HIV therapy
Merck & Co. Inc. (NYSE:MRK) and Codexis Inc. (NASDAQ:CDXS) researchers designed a way to synthesize HIV therapy islatravir (MK-8591) via

Read the full 294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE